Physician

Matthew J Klinge, MD

According to 2025 Medicare claims, Matthew Klinge, MD (NPI: 1457693533) practices gastroenterology in the Erie, PA market, with the plurality of this provider's patient population coming from Erie, PA. This provider's primary affiliated billing organization is REGIONAL HEALTH SERVICES INC (NPI: 1174520654; TIN: 251403958) and primary practice location at 16507-1423.

Klinge's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 465 traditional Medicare patients, billed 4,185 HCPCS/CPT codes, and received $151,350 in Medicare payments. The top billing code was 45380 (Biopsy of large bowel using a flexible endoscope). Part D data shows 2,114 prescription claims across 611 beneficiaries totaling $1,124,243 in drug costs, led by Stelara (Ustekinumab). DME data shows 51 claims. Open Payments data shows 15 records totaling $408. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $55,137 to $151,350. Similarly, Part D prescription costs have risen steadily, from $1,103 to $1,124,243. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	285	569	$55,137
2020	431	894	$79,431
2021	448	960	$89,473
2022	441	2,710	$113,135
2023	478	6,441	$178,194
2024	465	4,185	$151,350

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	21	$1,103
2016	N/R	16	$1,867
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	125	239	$173,552
2020	262	893	$489,532
2021	279	1,121	$638,267
2022	377	1,392	$402,122
2023	505	1,815	$612,352
2024	611	2,114	$1,124,243

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	38	$734
2022	N/R	29	$507
2023	N/R	43	$638
2024	N/R	51	$876

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
45380	Biopsy of large bowel using a flexible endoscope	88	89	$112
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	95	97	$97
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	64	80	$90
43239	Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope	106	107	$62
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	100	178	$60

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Stelara	Ustekinumab	13	673	$333,429
Xifaxan	Rifaximin	64	1,814	$195,869
Xeljanz	Tofacitinib Citrate	11	330	$73,866
Creon	Lipase/Protease/Amylase	21	774	$56,494
Ursodiol	Ursodiol	119	7,202	$18,757

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	12	$262
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$226
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$201
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	15	$187

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	15	$408	Takeda Pharmaceuticals U.S.A., Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Matthew J. Klinge, MD?

Tedicare shows public-source Medicare data for Matthew J. Klinge, MD (NPI 1457693533), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Matthew J. Klinge, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Matthew J. Klinge, MD?

Matthew J. Klinge, MD is linked to REGIONAL HEALTH SERVICES INC (billing NPI 1174520654) in the available physician profile data.

Does Matthew J. Klinge, MD have Open Payments data?

Matthew J. Klinge, MD has 15 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.